Notícias

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th

Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.

The new objective implies roughly 16% upside and reflects stronger expectations for J&J's pharmaceutical pipeline.

Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline

The Dow was on the rise early in Wednesday's trading session, and the gains were being felt broadly across the blue-chip index. The Dow Jones Industrial Average was up 0.6%, or 326 points, while the S&P 500 and Nasdaq Composite ticked higher, rising 0.

AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.

JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.

The orthopedics specialist aims to launch a knee robot in late 2028, followed by a shoulder robot in 2029.

Johnson & Johnson (NYSE: JNJ) was found liable by a Louisiana jury in a high-profile talc-related mesothelioma case, adding a fresh verdict to its ongoing talc litigation. The jury decision centers on alleged asbestos exposure from Johnson & Johnson talc products and raises questions about potential future legal costs for the company. This verdict contributes to the broader legal overhang that investors weigh alongside Johnson & Johnson's core healthcare operations and balance sheet...

Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.

Replacing nearly $47,000 a year in retirement income without touching principal sounds like a math problem, but the real trap is choosing the wrong yield tier and watching either your paycheck or your nest egg quietly shrink.

Medtronic (MDT) lifted its full-year outlook on Tuesday as the medical-device maker reported better-

Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.

CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.

This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.

JEPI's monthly payouts have quietly shrunk all year while the broader market surged past it, and the one event that could reverse both trends is now closer than most investors expect.

Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV. The approval marks the company’s second FDA-approved medicine this year, following the M

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.

Three consumer giants have kept raising their dividends through oil shocks, financial crises, and every other economic storm since 1970, and the cash flow numbers behind their streaks reveal why retirees treat them less like investments and more like utilities.

PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.

One of J&J's investments stands head-and-shoulders above the rest.

Converting a nest egg into a reliable monthly paycheck sounds straightforward until you realize the yield tier you choose can demand nearly three times as much capital for the same income target. A 79-year-old widow with fixed expenses and no room for error found a middle path most retirees overlook entirely.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.

Johnson & Johnson stock has delivered an 81.9% gain over the past three years, yet the valuation picture is split between an intrinsic value estimate that points to upside and market multiples that lean the other way. With recent approvals in key therapies alongside ongoing legal exposure, investors are weighing how much of Johnson & Johnson’s story is already reflected in the current share price. The 81.9% return over three years signals that Johnson & Johnson has rewarded longer term...

CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]

JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.